Literature DB >> 19268418

Grafting of protein L-binding activity onto recombinant antibody fragments.

Julien Muzard1, Sonia Adi-Bessalem, Matthieu Juste, Fatima Laraba-Djebari, Nicolas Aubrey, Philippe Billiald.   

Abstract

Recombinant antibody fragments consisting of variable domains can be easily produced in various host cells, but there is no universal system that can be used to purify and detect them in the free form or complexed with their antigen. Protein L (PpL) is a cell wall protein isolated from Peptostreptococcus magnus, which has been reported to interact with the V-KAPPA chain of some, but not all, antibodies. Here we grafted the V-KAPPA framework region 1 (FR1) sequence of a high-affinity PpL-binding antibody onto single-chain antibody fragments (scFvs), which have no reactivity with PpL. This substitution made it possible to purify and detect scFvs using PpL conjugates. It did not hinder scFv folding and expression in recombinant bacteria, and it did not interfere with their antigen-binding function. We also identified residue 12 as being potentially able to alter PpL binding. This study, therefore, suggests a way of engineering a PpL-binding site on any scFv without interfering with its function. This could provide a universally applicable method both for the rapid purification of functional recombinant antibody fragments and for their detection even when complexed with their antigen without requiring fusion to an epitope Flag.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268418     DOI: 10.1016/j.ab.2009.02.035

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  7 in total

1.  Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom.

Authors:  Anne di Tommaso; Matthieu O Juste; Marie-France Martin-Eauclaire; Isabelle Dimier-Poisson; Philippe Billiald; Nicolas Aubrey
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

2.  Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Authors:  Mark C Julian; Christine C Lee; Kathryn E Tiller; Lilia A Rabia; Evan K Day; Arthur J Schick; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2015-09-19       Impact factor: 1.650

3.  Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.

Authors:  Conor Fields; David O'Connell; Sujing Xiao; Gil U Lee; Philippe Billiald; Julien Muzard
Journal:  Nat Protoc       Date:  2013-05-16       Impact factor: 13.491

4.  A method to confer Protein L binding ability to any antibody fragment.

Authors:  Zineb Lakhrif; Martine Pugnière; Corinne Henriquet; Anne di Tommaso; Isabelle Dimier-Poisson; Philippe Billiald; Matthieu O Juste; Nicolas Aubrey
Journal:  MAbs       Date:  2015-12-18       Impact factor: 5.857

5.  Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.

Authors:  Kristell Lebozec; Martine Jandrot-Perrus; Gilles Avenard; Olivier Favre-Bulle; Philippe Billiald
Journal:  MAbs       Date:  2017-06-09       Impact factor: 5.857

6.  Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences.

Authors:  Thomas Cnudde; Zineb Lakhrif; Justine Bourgoin; Fanny Boursin; Catherine Horiot; Corinne Henriquet; Anne di Tommaso; Matthieu Olivier Juste; Isabella Gizzi Jiacomini; Isabelle Dimier-Poisson; Martine Pugnière; Marie-Nöelle Mévélec; Nicolas Aubrey
Journal:  Antibodies (Basel)       Date:  2020-04-15

7.  Loxoscelism: Advances and Challenges in the Design of Antibody Fragments with Therapeutic Potential.

Authors:  Sabrina Karim-Silva; Alessandra Becker-Finco; Isabella Gizzi Jiacomini; Fanny Boursin; Arnaud Leroy; Magali Noiray; Juliana de Moura; Nicolas Aubrey; Philippe Billiald; Larissa M Alvarenga
Journal:  Toxins (Basel)       Date:  2020-04-16       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.